Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | January 02, 2020 | January 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date January 02, 2020 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2030-01-02 | Direct | 10,000 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 10,000 · Balance 10,000 F1: This option was granted on January 2, 2020 and vests in full on December 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 2, 2020 and vests in full on December 31, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GreenLight Biosciences Holdings, PBC
Report date July 24, 2023 · Filed July 26, 2023
Section 16 reporting ended · disclosed 2023-07-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-24 transaction · row 1
1 source rowRow 1 · 2023-07-24 · Other · Disposed 896,058 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC ("Issuer"), SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to which Merger Sub completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of July 24, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $0.30 per Share, in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC ("Issuer"), SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to which Merger Sub completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of July 24, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $0.30 per Share, in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2023 Filed Jul 26, 2023 18:12 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | OtherCommon Stock | 896,058 | $0.30 | $268,817.40 |
DisclosureSEC source: 0000950170-23-034844 · ownership.xml · nonDerivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC ("Issuer"), SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to which Merger Sub completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of July 24, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $0.30 per Share, in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC ("Issuer"), SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to which Merger Sub completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of July 24, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $0.30 per Share, in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantStock Option (Right to Buy) · Derivative | 292,649 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · derivative · entry 7 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,649 Underlying: Common Stock · 292,649 shares Expires 2030-12-01 F3 · price: This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. F8 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest after one year of service and the remainder of the shares vested or shall vest in 36 equal monthly installments. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantStock Option (Right to Buy) · Derivative | 1,906,944 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · derivative · entry 6 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,944 Underlying: Common Stock · 1,906,944 shares Expires 2030-12-01 F3 · price: This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. F7 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantStock Option (Right to Buy) · Derivative | 668,830 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · derivative · entry 5 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,830 Underlying: Common Stock · 668,830 shares Expires 2029-12-29 F3 · price: This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. F6 · derivative.exercise_date: 20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting December 5, 2021. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantStock Option (Right to Buy) · Derivative | 1,982,609 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · derivative · entry 4 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982,609 Underlying: Common Stock · 1,982,609 shares Expires 2029-12-29 F3 · price: This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. F5 · derivative.exercise_date: 20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting December 5, 2021. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantStock Option (Right to Buy) · Derivative | 926,330 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · derivative · entry 3 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,330 Underlying: Common Stock · 926,330 shares Expires 2028-09-13 F3 · price: This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. F4 · derivative.exercise_date: 20% of the shares underlying the option vested or shall vest on September 12, 2018 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 12, 2018. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantStock Option (Right to Buy) · Derivative | 70,319 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · derivative · entry 2 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,319 Underlying: Common Stock · 70,319 shares Expires 2023-07-29 F3 · price: This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:26 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | GrantCommon Stock | 896,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-002726 · form4.xml · nonDerivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,058 F1 · price: Issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for capital stock previously issued by such company. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001209191-20-000997 · doc4.xml · derivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option was granted on January 2, 2020 and vests in full on December 31, 2020. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-19-037130 · doc4.xml · derivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 8,000 | $10.00 | $80,039.20 |
DisclosureSEC source: 0000899243-19-013080 · doc4.xml · nonDerivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 10,189 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's spouse on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $28.92 | $0.00 |
DisclosureSEC source: 0000899243-19-000269 · doc4.xml · derivative · entry 2 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-02 F2 · derivative.exercise_date: This option was granted on January 2, 2019 and vests in four equal consecutive annual installments beginning January 2, 2020. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $28.92 | $0.00 |
DisclosureSEC source: 0000899243-19-000269 · doc4.xml · derivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: This option was granted on January 2, 2019 and vests in full on the one year anniversary of the grant date. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:08 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031207 · doc4.xml · derivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of the one year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 11:30 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 100 | $35.00 | $3,500.00 |
DisclosureSEC source: 0000899243-18-029423 · doc4.xml · nonDerivative · entry 1 Zarur Juan Andrey · CIK 0001727404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,105 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.